1[1]Atkins MB.Immunotherapy and experimental approaches for metastatic melanoma[J].Hematol Oncol Clin North Am,1998,12:877-902, viii.
2[2]Gane E, Saliba F,Valdecasas GJ, et al.Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients:the Oral Ganciclovir International Transplantation Study Group [corrected][J].Lancet,1997,350:1729-1733.
3[3]Klatzmann D, Cherin P, Bensimon G, et al.A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma.Study Group on Gene Therapy of Metastatic Melanoma[J].Hum Gene Ther,1998,9:2585-2594.
4[4]Bonnekoh B, Greenhalgh DA, Bundman DS, et al.Adenoviral mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma[J].J Invest Dermatol,1996,106:1163-1168.
5[5]Schneeberger A,Goos M,Stingl G, et al.Management of malignant melanoma:new developments in immune and gene therapy[J].Clin Exp Dermatol,2000,25:509-519.
6[6]Dummer R, Bergh J, Karlsson Y, et al.Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors[J].Cancer Gene Ther,2000,7:1069-1076.
7[7]Castellano M, Parmiani G.Genes involved in melanoma:an overview of INK4a and other loci[J].Melanoma Res,1999,9:421-432.
8[8]Cheung KJ Jr,Li G.The tumor suppressor p33ING1 does not regulate migration and angiogenesis in melanoma cells[J].Int J Oncol,2002,21(6):1361-1364.
9[9]Putney SD, Brown J, Cucco C, et al.Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide[J].Antisense Nucleic Acid Drug Dev,1999,9:451-458.
10[10]Niu G, Heller R, Catlett-Falcone R, et al.Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo[J].Cancer Res,1999,59:5059-5063.
6[1]MACKIE R M,BRAY C A,HOLE D J.Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma[J].BMJ,2002,325(7375):1276-1277.
7[2]FOLKMAN J,HAHNFELDT P,HLATKY L.The logic of antiangiogenic gene therapy[M]// FRIEDMANN T.The development of human gene therapy.New York:Cold Spring Harbor Laboratory Press,1999:527-543.
8[4]FOLKMAN J.Angiogenesis in cancer,vascular,rheumatoid and other disease[J].Nat Med,1995,1(1):27-31.
9[5]BOEHM T,FOLKMAN J,BROWDER T,et al.Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance[J].Nature,1997,390(6658):404-407.
10[6]SHARPIRO R.Cytoplasmic ribonuclease inhibitor[M]// ABELSON J N,SIMON M I.Methods in enzymology.San Diego:Academic Press,2001:611-628.
